Sociodemographic and health characteristics of the total Newcastle 85+ cohort (n=845) and by gender
| Men (n=319) | Women (n=526) | Overall cohort (n=845) | p Value* | |
|---|---|---|---|---|
| Ethnicity % (N) | ||||
| White | 99.4 (316) | 99.8 (523) | 99.6 (839) | 0.272† |
| Living arrangements % (N) | ||||
| Standard housing | 83.4 (266) | 73.2 (385) | 77.0 (651) | 0.002† |
| Sheltered housing | 10.3 (33) | 14.3 (75) | 12.8 (108) | |
| Institutional care | 6.3 (20) | 12.6 (66) | 10.2 (86) | |
| Smoking % (N) | ||||
| Never | 25.6 (81) | 42.0 (220) | 35.8 (301) | <0.001† |
| Former | 69.9 (221) | 51.5 (270) | 58.5 (491) | |
| Current | 4.4 (14) | 6.5 (34) | 5.7 (48) | |
| Occupational exposures % (N) | ||||
| Heavy industry | 41.2 (126) | 16.6 (83) | 25.9 (209) | <0.001† |
| Coal mining | 11.4 (35) | 0.0 (0) | 4.3 (35) | <0.001‡ |
| Chemical industry | 11.1 (34) | 4.0 (20) | 6.7 (54) | <0.001† |
| Asbestos exposure | 28.9 (88) | 1.6 (8) | 12.0 (96) | <0.001† |
| Respiratory symptoms % (N) | ||||
| Cough | 28.3 (88) | 25.8 (129) | 26.7 (217) | 0.425† |
| Wheeze | 25.0 (78) | 20.2 (101) | 22.0 (179) | 0.109† |
| Sputum production | 40.7 (127) | 28.0 (140) | 32.9 (267) | <0.001 |
| MRC dyspnoea score % (N) | ||||
| 1 | 50.2 (123) | 40.5 (143) | 44.5 (266) | 0.048§ |
| 2 | 11.4 (28) | 19.0 (67) | 15.9 (95) | |
| 3 | 20.4 (50) | 17.6 (62) | 18.7 (112) | |
| 4 | 15.1 (37) | 17.0 (60) | 16.2 (97) | |
| 5 | 2.9 (7) | 6.0 (21) | 4.7 (28) | |
| Respiratory diagnoses % (N) | ||||
| COPD | 17.9 (57) | 15.8 (83) | 16.6 (140) | 0.429† |
| Asthma | 6.9 (22) | 12.7 (67) | 10.5 (89) | 0.007† |
| Bronchiectasis | 2.5 (8) | 1.5 (8) | 1.9 (16) | 0.308† |
| Pulmonary fibrosis | 0.0 (0) | 0.2 (1) | 0.1 (1) | 1.000‡ |
| Asbestosis | 1.6 (5) | 0.0 (0) | 0.6 (5) | 0.008‡ |
| Pneumoconiosis | 1.3 (4) | 0.0 (0) | 0.5 (4) | 0.020‡ |
| TB | 4.4 (14) | 4.9 (26) | 4.7 (40) | 0.713† |
| Respiratory medications | ||||
| Inhaled short-acting β-2 adrenoreceptor agonists | 9.1 (29) | 11.4 (60) | 10.5 (89) | 0.288† |
| Inhaled muscarinic antagonists | 3.8 (12) | 3.8 (20) | 3.8 (32) | 0.976† |
| Oral theophylline | 0.3 (1) | 0.5 (3) | 0.5 (4) | 0.598‡ |
| Combination short-acting bronchodilators | 0.6 (2) | 0.0 (0) | 0.2 (2) | 0.142‡ |
| Inhaled corticosteroids | 5.3 (17) | 7.8 (41) | 6.9 (58) | 0.169† |
| Combination inhaled Corticosteroids and long-acting β-2 adrenoreceptor agonists | 1.9 (6) | 2.1 (11) | 2.0 (17) | 0.833† |
| Oral leukotriene receptor antagonists | 0.0 (0) | 0.4 (2) | 0.2 (2) | 0.529‡ |
| Oral mucolytics | 0.6 (2) | 0.2 (1) | 0.4 (3) | 0.560‡ |
| At least one respiratory medication | ||||
| % (N) | 12.2 (39) | 14.5 (76) | 13.6 (115) | 0.361† |
| Disease count | ||||
| median (IQR) | 4 (3–6) | 5 (4–6) | 5 (3–6) | 0.074§ |
| Comorbid disease count | ||||
| median (IQR) | 4 (3–6) | 5 (4–6) | 5 (3–6) | 0.047§ |
*Comparison of men and women.
§Mann–Whitney U test.
†χ2 test.
‡Fisher's exact test,.
Denominators vary due to missing values.